Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.63 |
| ▸ | ITGAV | P06756 | 4/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | FABP1 | P07148 | 1/20 | 0.53 |
| ▸ | FABP6 | P51161 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14914649 | 0.98 | ITGB3 (0.61) | ITGB3ITGAVCYP1A2GAAFABP1 | |
| SCHEMBL4394126 | 0.90 | ITGB3 (0.64) | ITGB3ITGAVCYP1A2GAAFABP1 | |
| SCHEMBL2037116 | 0.88 | ITGB3 (0.70) | ITGB3ITGAVITGB5HDAC3HDAC4 | |
| SCHEMBL4398060 | 0.87 | ITGB3 (0.68) | ITGB3ITGAVITGB5HDAC3HDAC4 | |
| SCHEMBL4717622 | 0.87 | ITGB3 (0.68) | ITGB3ITGAVITGB5HDAC3HDAC4 | |
| SCHEMBL6302594 | 0.84 | CYP1A2 (0.53) | ITGB3ITGAVCYP1A2GAAFABP1 | |
| SCHEMBL13589546 | 0.84 | CYP2C19 (0.56) | ITGB3ITGAVCYP1A2GAAFABP1 | |
| SCHEMBL18541254 | 0.83 | GAA (0.50) | ITGB3ITGAVCYP1A2GAAFABP1 | |
| SCHEMBL18381352 | 0.82 | ITGB3 (0.62) | ITGB3ITGAVGAAITGB5ALDH1A1 | |
| SCHEMBL8180590 | 0.82 | ITGB3 (0.62) | ITGB3ITGAVGAAITGB5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110127869-B | Environment-friendly neutral scale and corrosion inhibitor for oil extraction and preparation method thereof | 黑龙江益瑞化工有限公司 | 2020-10-09 | — | — | CN | claimed |
| EP-2978750-B1 | \"SYNTHESIS OF DABIGATRAN\ | USV PRIVATE LTD (IN) | 2020-03-04 | — | — | EP | claimed |
| EP-3165521-B1 | METHOD OF PREPARING DABIGATRAN ETEXILATE INTERMEDIATE AND INTERMEDIATE COMPOUND | SHANGHAI INST PHARMACEUTICAL IND (CN) | 2019-01-16 | — | — | EP | claimed |
| EP-2834224-B1 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND SALTS THEREOF | MSN LAB LTD (IN) | 2018-06-06 | — | — | EP | claimed |
| US-9688657-B2 | Synthesis of dabigatran | USV PRIVATE LIMITED (IN) | 2017-06-27 | — | — | US | claimed |
| EP-1880711-B1 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO CO LTD (JP) | 2016-07-20 | — | — | EP | claimed |
| US-20160060248-A1 | SYNTHESIS OF DABIGATRAN | USV PRIVATE LIMITED (IN) | 2016-03-03 | — | — | US | claimed |
| EP-2978750-A2 | \"SYNTHESIS OF DABIGATRAN\ | USV Limited (IN) | 2016-02-03 | — | — | EP | claimed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | claimed |
| WO-2014167577-A2 | \"SYNTHESIS OF DABIGATRAN\ | USV LIMITED (IN) | 2014-10-16 | — | — | WO | claimed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | claimed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | claimed |
| EP-0966454-B1 | DISUBSTITUTED BICYCLIC HETEROCYCLES, THEIR PRODUCTION AND USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-05-07 | — | — | EP | claimed |
| EP-4584387-A1 | MULITIVALENCY FOR ENZYME INHIBITION | Indiana University Research and Technology Corporation (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2024054372-A1 | MULITIVALENCY FOR ENZYME INHIBITION | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2024-03-14 | — | — | WO | disclosed |
| US-6159964-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0906103-A4 | — | — | 1999-04-07 | — | — | EP | disclosed |
| EP-0906103-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997024124-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | KRAS, FOLR2, SLC19A1 | ITGB3 2978/4885ITGAV 1970/4885CYP1A2 4191/4885 |
| US-20160060248-A1 | SYNTHESIS OF DABIGATRAN | ESD, F2, PROC | ITGB3 91/4885ITGAV 513/4885CYP1A2 247/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | ITGB3 4773/4885ITGAV 4824/4885CYP1A2 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.